Anti-Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid Arthritis.

Laura C CappelliDavid HinesHong WangClifton O Bingham Erika Darrah

Published in: ACR open rheumatology (2023)

Differences in prevalence, clinical associations, and treatment-response outcomes according to anti-PAD4 antibody status in early and established RA suggests the existence of a therapeutic window to prevent the accumulation of irreversible joint damage in early patients with RA with anti-PAD4 antibodies.

Keyphrases

rheumatoid arthritis
disease activity
systemic lupus erythematosus
interstitial lung disease
risk factors
oxidative stress
type diabetes